MGMT and central nervous system cancer: Methylation of the MGMT promoter has been observed in approximately 50% of grade 4 gliomas, commonly referred to as glioblastoma multiforme (GBM).14 MGMT status holds strong prognostic value and potential predictive information on the benefit of alkylating chemotherapy.15